Is IRadimed Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for IRadimed Corp. has moved from expensive to attractive, indicating a shift in perception towards the stock's value. The company is currently considered undervalued based on its financial metrics. Key ratios include a P/E ratio of 39, an EV to EBITDA of 30.68, and a Price to Book Value of 8.54, which suggest that the stock is trading at a reasonable valuation compared to its peers.
In comparison to its peers, IRadimed Corp. has a higher P/E ratio than Artivion, Inc. and BioLife Solutions, Inc., which are both classified as risky, with negative P/E ratios. Despite this, IRadimed's strong ROCE of 56.93% and ROE of 21.97% highlight its efficient use of capital. Additionally, the company has outperformed the S&P 500 across multiple periods, with a year-to-date return of 33.51% compared to the S&P 500's 13.30%, reinforcing the attractiveness of its current valuation.